AIMC Topic: Certolizumab Pegol

Clear Filters Showing 1 to 1 of 1 articles

Machine Learning to Predict Anti-Tumor Necrosis Factor Drug Responses of Rheumatoid Arthritis Patients by Integrating Clinical and Genetic Markers.

Arthritis & rheumatology (Hoboken, N.J.) Nov 4, 2019
OBJECTIVE: Accurate prediction of treatment responses in rheumatoid arthritis (RA) patients can provide valuable information on effective drug selection. Anti-tumor necrosis factor (anti-TNF) drugs are an important second-line treatment after methotr...
Humans Machine Learning Tumor Necrosis Factor-alpha Female Reproducibility of Results Male Middle Aged Severity of Illness Index Arthritis, Rheumatoid Polymorphism, Single Nucleotide Treatment Outcome Regression Analysis Predictive Value of Tests Infliximab Genetic Markers Methotrexate Adalimumab Outcome Assessment, Health Care Antirheumatic Agents Normal Distribution Etanercept Certolizumab Pegol
View on PubMed DOI
Popular Topics
Recent Journals